Literature DB >> 19308743

[In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin].

M S Hernández1, J A García, J L Muñoz.   

Abstract

In vitro activity of fosfomycin, compared with other antibiotics used for urinary tract infections (UTI), against extended spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from UTIs, was determined. The activity of fosfomycin, co-trimoxazole, ciprofloxacin, nitrofurantoin, amoxicillin/clavulanic acid and gentamicin against 71 ESBL-producing E. coli clinical isolates and 13 ESBL-producing K. pneumoniae clinical isolates obtained from UTI was studied by the agar-dilution method or E-test. E. coli isolates produced mainly CTX-M type ESBL (76.1%), especially CTX-M 14 (56.3%). K. pneumoniae isolates produced most predominantly SHV-type ESBL (92.3%), mainly SHV-2 (76.9%). Gentamicin (4.4%), fosfomycin (5.6%) and nitrofurantoin (5.6%) showed the lowest resistance proportions against E. coli. Co-trimoxazole and ciprofloxacin (7.7%) showed the lowest resistance proportions against K. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19308743

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  3 in total

1.  Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.

Authors:  Antonia C Kastoris; Petros I Rafailidis; Evridiki K Vouloumanou; Ioannis D Gkegkes; Matthew E Falagas
Journal:  Eur J Clin Pharmacol       Date:  2010-02-26       Impact factor: 2.953

2.  Susceptibility of urinary tract bacteria to fosfomycin.

Authors:  Sofia Maraki; George Samonis; Petros I Rafailidis; Evridiki K Vouloumanou; Emmanuel Mavromanolakis; Matthew E Falagas
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

3.  Bacterial sensitivity to fosfomycin in pregnant women with urinary infection.

Authors:  Rodrigo Batista Souza; Daisson José Trevisol; Fabiana Schuelter-Trevisol
Journal:  Braz J Infect Dis       Date:  2015-01-24       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.